WALDENSTROM?S MACROGLOBULINEMIA EXPRESS B-CELL MATURATION ANTIGEN AND SERUM LEVELS CORRELATE WITH DISEASE STATUS AND CONVENTIONAL M-PROTEIN AND IGM LEVELS
(Abstract release date: 05/21/15)
EHA Library. Berenson J. 06/12/15; 102911; PB1891
Disclosure(s): Institute for Myeloma & Bone Cancer ResearchHematology/Oncology
Mr. James Berenson
Contributions
Contributions
Abstract
Abstract: PB1891
Type: Publication Only
Background
Waldenström's macroglobulinemia (WM) is an incurable B-cell lymphoplasmacytic lymphoma. B-cell maturation antigen (BCMA) is expressed on malignant B cells and we have previously shown that serum BCMA levels are elevated in multiple myeloma (MM) patients and correlate with disease status in multiple myeloma (MM) patients.
Aims
Our objective was to determine whether BCMA is present in WM; and, furthermore, whether its serum levels also correlate with disease status and track with conventional tumor markers for patients with WM.
Methods
Data was obtained on 20 WM patients who received treatment in a single clinic specializing in monoclonal gammopathies. Mann-Whitney analysis was used to measure statistical significance (p<0.05). Immunohistochemical staining and flow cytometric analysis was used to determine the expression of BCMA on WM cells.
Results
First, we found that BCMA is highly expressed on the surface of tumor cells from the bone marrow of WM patients using both immunohistochemical and flow cytometric analysis. Next, we compared serum BCMA levels from untreated WM patients (n=9) to healthy individuals (n=14), and the levels were markedly higher in WM patients (p<0.0001). Next, BCMA levels in WM patient sera were also correlated with disease status at the time during which the sample was collected. Serum from patients achieving > partial response (n=7) showed significantly lower levels of BCMA than samples from patients with stable disease (n=4) or progressive disease (n=7; p=0.003 and p=0.0003, respectively). Additionally, the BCMA levels of seven WM patients were correlated with the serum M-protein and IgM levels of these patients during the course of their therapy. Changes in serum BCMA levels correlated with changes in serum M-protein as well as IgM levels.
Summary
These results indicate that BCMA is present on the malignant cells from WM patients and serum levels of this protein can be used as a potential marker for tracking the course of their disease.
Keyword(s): Waldenstrom's macroglobulinemia
Session topic: Publication Only
Type: Publication Only
Background
Waldenström's macroglobulinemia (WM) is an incurable B-cell lymphoplasmacytic lymphoma. B-cell maturation antigen (BCMA) is expressed on malignant B cells and we have previously shown that serum BCMA levels are elevated in multiple myeloma (MM) patients and correlate with disease status in multiple myeloma (MM) patients.
Aims
Our objective was to determine whether BCMA is present in WM; and, furthermore, whether its serum levels also correlate with disease status and track with conventional tumor markers for patients with WM.
Methods
Data was obtained on 20 WM patients who received treatment in a single clinic specializing in monoclonal gammopathies. Mann-Whitney analysis was used to measure statistical significance (p<0.05). Immunohistochemical staining and flow cytometric analysis was used to determine the expression of BCMA on WM cells.
Results
First, we found that BCMA is highly expressed on the surface of tumor cells from the bone marrow of WM patients using both immunohistochemical and flow cytometric analysis. Next, we compared serum BCMA levels from untreated WM patients (n=9) to healthy individuals (n=14), and the levels were markedly higher in WM patients (p<0.0001). Next, BCMA levels in WM patient sera were also correlated with disease status at the time during which the sample was collected. Serum from patients achieving > partial response (n=7) showed significantly lower levels of BCMA than samples from patients with stable disease (n=4) or progressive disease (n=7; p=0.003 and p=0.0003, respectively). Additionally, the BCMA levels of seven WM patients were correlated with the serum M-protein and IgM levels of these patients during the course of their therapy. Changes in serum BCMA levels correlated with changes in serum M-protein as well as IgM levels.
Summary
These results indicate that BCMA is present on the malignant cells from WM patients and serum levels of this protein can be used as a potential marker for tracking the course of their disease.
Keyword(s): Waldenstrom's macroglobulinemia
Session topic: Publication Only
Abstract: PB1891
Type: Publication Only
Background
Waldenström's macroglobulinemia (WM) is an incurable B-cell lymphoplasmacytic lymphoma. B-cell maturation antigen (BCMA) is expressed on malignant B cells and we have previously shown that serum BCMA levels are elevated in multiple myeloma (MM) patients and correlate with disease status in multiple myeloma (MM) patients.
Aims
Our objective was to determine whether BCMA is present in WM; and, furthermore, whether its serum levels also correlate with disease status and track with conventional tumor markers for patients with WM.
Methods
Data was obtained on 20 WM patients who received treatment in a single clinic specializing in monoclonal gammopathies. Mann-Whitney analysis was used to measure statistical significance (p<0.05). Immunohistochemical staining and flow cytometric analysis was used to determine the expression of BCMA on WM cells.
Results
First, we found that BCMA is highly expressed on the surface of tumor cells from the bone marrow of WM patients using both immunohistochemical and flow cytometric analysis. Next, we compared serum BCMA levels from untreated WM patients (n=9) to healthy individuals (n=14), and the levels were markedly higher in WM patients (p<0.0001). Next, BCMA levels in WM patient sera were also correlated with disease status at the time during which the sample was collected. Serum from patients achieving > partial response (n=7) showed significantly lower levels of BCMA than samples from patients with stable disease (n=4) or progressive disease (n=7; p=0.003 and p=0.0003, respectively). Additionally, the BCMA levels of seven WM patients were correlated with the serum M-protein and IgM levels of these patients during the course of their therapy. Changes in serum BCMA levels correlated with changes in serum M-protein as well as IgM levels.
Summary
These results indicate that BCMA is present on the malignant cells from WM patients and serum levels of this protein can be used as a potential marker for tracking the course of their disease.
Keyword(s): Waldenstrom's macroglobulinemia
Session topic: Publication Only
Type: Publication Only
Background
Waldenström's macroglobulinemia (WM) is an incurable B-cell lymphoplasmacytic lymphoma. B-cell maturation antigen (BCMA) is expressed on malignant B cells and we have previously shown that serum BCMA levels are elevated in multiple myeloma (MM) patients and correlate with disease status in multiple myeloma (MM) patients.
Aims
Our objective was to determine whether BCMA is present in WM; and, furthermore, whether its serum levels also correlate with disease status and track with conventional tumor markers for patients with WM.
Methods
Data was obtained on 20 WM patients who received treatment in a single clinic specializing in monoclonal gammopathies. Mann-Whitney analysis was used to measure statistical significance (p<0.05). Immunohistochemical staining and flow cytometric analysis was used to determine the expression of BCMA on WM cells.
Results
First, we found that BCMA is highly expressed on the surface of tumor cells from the bone marrow of WM patients using both immunohistochemical and flow cytometric analysis. Next, we compared serum BCMA levels from untreated WM patients (n=9) to healthy individuals (n=14), and the levels were markedly higher in WM patients (p<0.0001). Next, BCMA levels in WM patient sera were also correlated with disease status at the time during which the sample was collected. Serum from patients achieving > partial response (n=7) showed significantly lower levels of BCMA than samples from patients with stable disease (n=4) or progressive disease (n=7; p=0.003 and p=0.0003, respectively). Additionally, the BCMA levels of seven WM patients were correlated with the serum M-protein and IgM levels of these patients during the course of their therapy. Changes in serum BCMA levels correlated with changes in serum M-protein as well as IgM levels.
Summary
These results indicate that BCMA is present on the malignant cells from WM patients and serum levels of this protein can be used as a potential marker for tracking the course of their disease.
Keyword(s): Waldenstrom's macroglobulinemia
Session topic: Publication Only
{{ help_message }}
{{filter}}